Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes

. 2022 Feb 1;45(2):e32-e33.

doi: 10.2337/dc21-1800.

Affiliations

¹ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL.
² Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA.
³ Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
⁴ Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.

Hui Shao et al. Diabetes Care. 2022.

. 2022 Feb 1;45(2):e32-e33.

doi: 10.2337/dc21-1800.

¹ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL.
² Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA.
³ Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
⁴ Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA.

No abstract available

Cited by

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.
Khedagi A, Hoke C, Kelsey M, Coviello A, Jones WS, Jackson LR 2nd, Patel MR, McGarrah RW, Pagidipati NJ, Shah NP. Khedagi A, et al. Am J Prev Cardiol. 2023 Feb 24;13:100477. doi: 10.1016/j.ajpc.2023.100477. eCollection 2023 Mar. Am J Prev Cardiol. 2023. PMID: 36915710 Free PMC article. Review.
Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
Li C, Guo S, Huo J, Gao Y, Yan Y, Zhao Z. Li C, et al. Front Endocrinol (Lausanne). 2022 Oct 7;13:987081. doi: 10.3389/fendo.2022.987081. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36277697 Free PMC article.